| Literature DB >> 12370762 |
D F Hayes1, T M Walker, B Singh, E S Vitetta, J W Uhr, S Gross, C Rao, G V Doyle, L W M M Terstappen.
Abstract
Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating epithelial cells (CECs) a minimum of 4 times over the course of treatment. In 7 of the 10 CEC+ patients, HER-2 expression was detected on the CECs. CECs expressing HER-2 varied among patients and in serial samples from the same patient including a shift from HER-2- to HER-2+ CECs. These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12370762 DOI： 10.3892/ijo.21.5.1111
Source DB: PubMed Journal: Int J Oncol ISSN： 1019-6439 Impact factor: 5.650